文献速递妇科产科

比较左炔诺孕酮宫内缓释系统与宫腔镜下剖宫产切口憩室切除术治疗剖宫产子宫瘢痕憩室相关经后点滴出血:一项随机、开放标签、对照试验

Comparing levonorgestrel intrauterine system with hysteroscopic niche resection in women with postmenstrual spotting related to a niche in the uterine cesarean scar: a randomized, open-label, controlled trial.
PubMed 文献 · Am J Obstet Gynecol · 2023-03-17

该随机、开放标签、对照试验在中国上海一家医疗中心纳入208例子宫瘢痕憩室相关经后点滴出血女性,比较52 mg左炔诺孕酮宫内缓释系统与宫腔镜下憩室切除术的疗效。主要结局(6个月时点滴出血天数减少≥50%)两组分别为78.4%与73.1%(RR 1.07,95%CI 0.92-1.25;P=.370),差异无统计学意义;但左炔诺孕酮宫内缓释系统组自9个月起点滴出血减少更显著,自6个月起点滴出血天数和总出血天数更少,自3个月起盆腔痛更轻。

要点

  • 6个月时点滴出血减少≥50%者左炔诺孕酮宫内缓释系统组78.4%(80/102)vs 宫腔镜切除术组73.1%(76/104),RR 1.07(95%CI 0.92-1.25),无显著差异。
  • 自9个月起左炔诺孕酮宫内缓释系统组点滴出血减少更显著:9个月89.2% vs 72.1%(RR 1.24,95%CI 1.08-1.42),12个月90.2% vs 70.2%(RR 1.29,95%CI 1.12-1.48)。
  • 左炔诺孕酮宫内缓释系统组自6个月起点滴出血天数与总出血天数更少(均P<.001),自3个月起盆腔痛更轻(均P<.010);两组均未报告干预相关并发症。

核心结论

  • 在憩室相关经后点滴出血女性中,左炔诺孕酮宫内缓释系统在6个月时使点滴出血天数减少至少50%方面并不优于宫腔镜下憩室切除术;但左炔诺孕酮宫内缓释系统自9个月起减少点滴出血更优,并自6个月起减少点滴出血绝对天数、自3个月起减轻盆腔痛。

研究设计与样本

  • 随机、开放标签、对照试验,2019年9月至2022年1月在中国上海一家医疗中心纳入208例剖宫产术后经后点滴出血、磁共振成像示憩室深度至少2 mm且残余肌层至少2.2 mm、未来一年无妊娠意愿的女性,随机分为52 mg左炔诺孕酮宫内缓释系统组(N=104)与宫腔镜下憩室切除术组(N=104),采用意向性治疗分析评价疗效与安全性。

主要发现

  • 6个月随访时点滴出血减少≥50%者左炔诺孕酮宫内缓释系统组78.4%(80/102)vs 宫腔镜下憩室切除术组73.1%(76/104),相对风险1.07(95%置信区间0.92-1.25),P=.370。点滴出血随时间减少(P趋势=.001),左炔诺孕酮宫内缓释系统组减少更明显(P=.001),时间与治疗存在显著交互作用(P=.007)。自9个月起左炔诺孕酮宫内缓释系统组点滴出血减少更显著:9个月89.2% vs 72.1%,相对风险1.24(95%置信区间1.08-1.42);12个月90.2% vs 70.2%,相对风险1.29(95%置信区间1.12-1.48)。与宫腔镜下憩室切除术组相比,左炔诺孕酮宫内缓释系统组自6个月起点滴出血天数和总出血天数显著更少(均P<.001),自3个月起盆腔痛更轻(均P<.010)。两组均未报告干预相关并发症;随访期间11例(10.8%)女性报告激素相关副作用,左炔诺孕酮宫内缓释系统组2例(2.0%)发生自发性部分脱落,宫腔镜下憩室切除术组报告3例非意愿妊娠。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postmenstrual spotting and chronic pelvic pain after cesarean delivery are associated with the presence of niches. Levonorgestrel intrauterine system (52 mg) and hysteroscopic niche resection have been shown to relieve niche-related symptoms at 6 months after the intervention. OBJECTIVE: This trial aimed to compare the effectiveness of 52-mg levonorgestrel intrauterine system with that of hysteroscopic niche resection in reducing niche-related postmenstrual spotting. STUDY DESIGN: This randomized, open-label, controlled trial was conducted at a medical center in Shanghai, China. Women with symptoms of postmenstrual spotting after cesarean delivery, with a niche depth of at least 2 mm and residual myometrium of at least 2.2 mm on magnetic resonance imaging, and no intention to conceive within the next year were randomly assigned to receive treatment with 52-mg levonorgestrel intrauterine system or hysteroscopic niche resection. The primary outcome was the reduction in postmenstrual spotting at 6 months after randomization, defined as the percentage of women with a reduction of at least 50% in spotting days relative to baseline. Efficacy and safety were assessed using intention-to-treat analysis. RESULTS: Between September 2019 and January 2022, 208 women were randomized into the levonorgestrel intrauterine system group (N=104) or the hysteroscopic niche resection group (N=104). At the 6-month follow-up, a 50% reduction in spotting had occurred in 78.4% (80/102) of women in the levonorgestrel intrauterine system group and in 73.1% (76/104) of women in the hysteroscopic niche resection group (relative risk, 1.07 [95% confidence interval, 0.92-1.25]; P=.370). Spotting decreased over time (Ptrend=.001), with a stronger reduction observed in the levonorgestrel intrauterine system group (P=.001). There was also a significant interaction between time and treatment (P=.007). From 9 months onward, a more significant reduction in spotting was observed in the levonorgestrel intrauterine system group than in the hysteroscopic niche resection group (9 months, 89.2% vs 72.1%; relative risk, 1.24 [95% confidence interval, 1.08-1.42]; 12 months, 90.2% vs 70.2%; relative risk, 1.29 [95% confidence interval, 1.12-1.48]). Moreover, compared with the hysteroscopic niche resection group, the levonorgestrel intrauterine system group had significantly fewer postmenstrual spotting days and total bleeding days from 6 months onward (all P<.001), and less pelvic pain from 3 months onward (all P<.010). No intervention-related complications were reported in any group. During follow-up, 11 (10.8%) women reported hormone-related side effects, and 2 women (2.0%) in the levonorgestrel intrauterine system group had spontaneous partial expulsion. Meanwhile, 3 unintended pregnancies were reported in the hysteroscopic niche resection group. CONCLUSION: In women with niche-related postmenstrual spotting, the levonorgestrel intrauterine system was not more effective than hysteroscopic niche resection in reducing the number of spotting days by at least 50% at 6 months. However, the levonorgestrel intrauterine system was superior in reducing spotting from 9 months onward, and it reduced the absolute number of spotting days from 6 months onward and pelvic pain from 3 months onward.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Zhang J, Zhu C, Yan L, et al. Comparing levonorgestrel intrauterine system with hysteroscopic niche resection in women with postmenstrual spotting related to a niche in the uterine cesarean scar: a randomized, open-label, controlled trial. Am J Obstet Gynecol. 2023. PMID: 36935068. doi:10.1016/j.ajog.2023.03.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。